Parameters affecting the ex vivo cytotoxic drug sensitivity of human hematopoietic cells

Journal of Experimental Therapeutics and Oncology

Volumn 2, Issue 1, 2002, Pages 53-63

  Bosanquet, Andrew G ^a,b   Burlton, Alison R ^a   Bell, Philip B ^a,b  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

Cytotoxicity; Differential staining cytotoxicity assay; Drug effects; Ex vivo drug evaluation; Normal cells; Therapeutic index; Tumor cells

Indexed keywords

ACLARUBICIN; AMSACRINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHYLPREDNISOLONE; MITOMYCIN; MITOXANTRONE; PENTOSTATIN; PREDNISOLONE; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

AGE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL ISOLATION; CELL LINEAGE; CELL STRUCTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOID CELL; MACROPHAGE; MONONUCLEAR CELL; PRIORITY JOURNAL; SEX DIFFERENCE; SOLID TUMOR; TUMOR CELL; ADULT; AGED; BONE MARROW; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HEMATOPOIETIC SYSTEM; MALE; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CELL LINEAGE; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC SYSTEM; HUMAN; MALE; MIDDLE AGE; HUMANS; MIDDLE AGED;

EID: 0036007546     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2002.01007.x     Document Type: Article

References (37)

1. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood
2. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators
3. Mononuclear cells contaminating leukemic samples tested for cellular drug reistance using the MTT assay
4. Growth characteristics of nonmalignant cells in the ATP cell viability assay
5. Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology
6. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay
7. Effect of cell isolation methods and drug concentration on the use of the differential staining cytotoxicity (DISC) assay with solid tumours
8. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia
9. Fludarabine: Phosphate or no phosphate, that is the confusion
10. Ex vivo assessment of drug response by differential staining cytotoxicity (DISC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia
11. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: Rationale for cryopreserving adapted-dose purged marrow early in first complete remission
12. Sensitivity of human CFU-GM to mafosfamide: Analysis of the factors affecting individual variations
13. In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow
14. Failure to induce resistance to cytotoxic drugs in normal lymphocytes
15. Turning the tables - Making normal marrow resistant to chemotherapy
16. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vitro exposure to doxorubicin
17. Clinical drug resistance: The role of factors other than P-glycoprotein
18. Thioguanine-resistant mutations induced by cytotoxic drugs in lymphocytes of patients with connective tissue diseases
19. The emergence of 6-thioguanine-resistant lymphocytes in pediatric cancer patients
20. Chlorambucil-induced chromosome damage to human lymphocytes
21. Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma
22. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
23. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
24. Activity of oxaliplatin against human tumor colony-forming units
25. Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: Results with 8-chloro-cAMP
26. Antineoplastic drug screening belongs in the laboratory, not in the clinic
27. Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging
28. Selective tumor localisation and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes
29. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists
30. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
31. Chemosensitivity testing of human tumors using a microplate ATP luminescence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma
32. Laboratory prediction of clinical chemotherapeutic drug resistance: A working model exemplified by acute leukemia
33. The DiSC assay - 10 Years and 2000 tests further on
34. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests
35. In vitro and in vivo toxicity of acetyldinaline (CI-994) to murine myelopoiesis and megakaryocytopoiesis
36. Methylprednisolone in advanced chronic lymphocytic leukaemia: Rationale for, and effectiveness of treatment suggested by DiSC assay
37. Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay